查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613332

皮肤科治疗市场：按治疗层级、给药途径、适应症、最终用户、分销管道 - 全球预测 2025-2030

Dermatology Drugs Market by Therapeutic Class (Antifungals, Corticosteroids, Immunosuppressants), Route of Administration (Oral, Parenteral Injection, Topical), Indication Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年皮肤科治疗市场规模为314亿美元，预计2024年将达342.3亿美元，复合年增长率为9.83%，2030年将达605.6亿美元。

皮肤病治疗的范围包括广泛的治疗产品，旨在治疗痤疮、干癣、湿疹和皮肤感染疾病等皮肤相关问题。皮肤科治疗在缓解症状、改善皮肤健康和增强患者信心方面发挥重要作用。最终用途主要包括医院、皮肤科诊所、药房和私人消费者。市场的推动因素包括人们对皮肤病的认识不断提高、药物配方的进步以及对微创治疗的需求不断增长。随着远距皮肤病学和个人化医疗方法的兴起，以及越来越多的患有皮肤病的老年人口，预计会出现新的商机。与生物技术公司的策略联盟以及透过数位平台推广可以提供利润丰厚的成长机会。

主要市场统计
基准年[2023] 314亿美元
预测年份 [2024] 342.3亿美元
预测年份 [2030] 605.6亿美元
复合年增长率（%） 9.83%

然而，市场面临一些挑战，包括严格的监管流程、高昂的研发成本以及与皮肤病治疗相关的潜在副作用。此外，新兴市场的可及性差以及学名药的竞争也是市场扩张的主要障碍。生物製药、药物传输系统中的奈米技术以及有机和天然皮肤病产品的开发等领域提供了有前景的成长途径。探索人工智慧主导的解决方案来预测皮肤状况和优化药物功效也可能彻底改变该领域。皮肤科药品市场的本质是高度动态的，其特点是技术快速进步和消费者对更安全、更有效的治疗方法的偏好不断变化。希望在这一领域获得优势的公司必须专注于全面的研究和开发，并与医疗保健提供者和监管机构建立牢固的合作伙伴关係。对不断变化的患者需求和监管环境保持敏感非常重要。此外，透过资料分析获得深入的市场洞察对于主动应对潜在的市场变化并灵活响应新趋势和消费者期望是必要的。总体而言，以患者为中心的方法与创新相结合对于克服挑战并最大限度地发挥皮肤病治疗市场的成长潜力至关重要。

市场动态：揭示快速发展的皮肤科治疗市场的关键市场洞察

供需的动态交互作用正在改变皮肤科治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 干癣、湿疹、痤疮和皮肤癌等皮肤病的盛行率增加
    • 药物开发方面的技术进步和强大的皮肤科治疗产品线
    • 越来越多地采用生物製药来抗治疗性疾病
  • 市场限制因素
    • 严格而漫长的监管核准流程
  • 市场机会
    • 加大个人化医疗投入，远端医疗应用不断增多
    • 皮肤科产品向天然和有机成分的重大转变
  • 市场挑战
    • 处理成本高、监管政策严格

波特五力：驾驭皮肤科药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解皮肤科药物市场的外部影响

外部宏观环境因素在塑造皮肤科治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解皮肤科治疗药物市场的竞争状况

皮肤病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵皮肤病治疗市场供应商的绩效评估

FPNV定位矩阵是评估皮肤科治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划皮肤科治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，皮肤病治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 干癣、湿疹、痤疮和皮肤癌等皮肤病的增加
      • 药物开发的技术进步和强大的皮肤科药物产品线
      • 越来越多地采用生物製药来抗治疗性疾病
    • 抑制因素
      • 严格而漫长的监管核准流程
    • 机会
      • 对个人化医疗的新投资和远端医疗应用的增加
      • 皮肤科产品向天然和有机成分的重大转变
    • 任务
      • 处理成本高、监管政策严格
  • 市场区隔分析
    • 治疗层级：免疫抑制剂在皮肤科的普及，用于治疗严重或难治性皮肤病
    • 最终使用者：由于社会对外表和健康的日益重视，对美容和皮肤科诊所的兴趣日益增加。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗层级的皮肤科药物市场

  • 抗真菌药物
  • 皮质类固醇
  • 免疫抑制剂
  • 类视色素A

第七章 皮肤科治疗药物市场：依给药途径分类

  • 口服
  • 肠外注射
  • 话题

第 8 章：按适应症类型分類的皮肤科治疗药物市场

  • 粉刺
  • 异位性皮肤炎
  • 干癣
  • 皮肤癌

第九章皮肤科治疗药物市场：依最终使用者分类

  • 美容/皮肤科诊所
  • 诊断中心及实验室
  • 医院

第10章皮肤科治疗药物市场：依分销管道分类

  • 医院药房
  • 零售药房

第十一章 北美和南美皮肤科药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区皮肤科治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲皮肤科治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Almirall 与微软宣布合作开发皮肤病新治疗方法
    • FDA核准Arcutis 的 ZORYVE（罗氟司特）外用泡沫 0.3% 用于治疗脂漏性皮肤炎
    • 礼来公司进军皮肤科领域，推出干癣治疗药物
  • 战略分析和建议

公司名单

  • Allergan plc by Abbvie Inc.
  • Almirall SA
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Asterisk Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • DermBiont, Inc.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma SA
  • GlaxoSmithkline plc
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Roivant Sciences Ltd.
  • Shinom Cosmeceuticals
Product Code: MRR-950610B5BBD5

The Dermatology Drugs Market was valued at USD 31.40 billion in 2023, expected to reach USD 34.23 billion in 2024, and is projected to grow at a CAGR of 9.83%, to USD 60.56 billion by 2030.

The scope of dermatology drugs encompasses a wide range of therapeutic products designed to treat skin-related issues, including acne, psoriasis, eczema, and skin infections. Dermatology drugs play a crucial role in alleviating symptoms, improving skin health, and boosting patient confidence. The end-use scope primarily includes hospitals, dermatology clinics, pharmacies, and individual consumers. The market is driven by increasing awareness of skin conditions, advances in pharmaceutical formulations, and a growing demand for minimally invasive treatments. Emerging opportunities are anticipated due to the rise in teledermatology and personalized medicine approaches, as well as the expanding geriatric population experiencing skin ailments. Strategic partnerships with biotech firms and leveraging digital platforms for outreach can present lucrative growth opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 31.40 billion
Estimated Year [2024] USD 34.23 billion
Forecast Year [2030] USD 60.56 billion
CAGR (%) 9.83%

However, the market confronts several challenges, such as stringent regulatory processes, high R&D costs, and the potential side effects associated with dermatology drugs. Limited accessibility in developing regions and heavy competition from generic drugs also pose significant barriers to market expansion. Innovation is key to overcoming these obstacles; areas like biopharmaceuticals, nanotechnology in drug delivery systems, and the development of organic and natural-based dermatology products offer promising avenues for growth. The exploration of AI-driven solutions for predicting skin conditions or optimizing drug efficacy could also revolutionize the sector. The nature of the dermatology drug market is highly dynamic, characterized by rapid technological advancements and a consumer preference shift towards safer, more effective treatments. Companies looking to assert dominance in this sphere must emphasize comprehensive research and development, alongside fostering strong alliances with healthcare providers and regulatory bodies. Remaining attuned to the evolving patient needs and regulatory landscapes will be critical. Additionally, gaining detailed market insights through data analytics will be necessary to preemptively address potential market shifts, ensuring agile adaptations to emerging trends and consumer expectations. Overall, a patient-centric approach, coupled with innovation, will be paramount in navigating the challenges and maximizing the growth potential within the dermatology drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dermatology Drugs Market

The Dermatology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
    • Technological advancements in drug development, along with a strong pipeline of dermatological drugs
    • Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
  • Market Restraints
    • Stringent and time-consuming regulatory approval process
  • Market Opportunities
    • Emerging investment in personalized medicine, and rising application in telemedicine
    • Notable shift towards natural and organic ingredients in dermatological products
  • Market Challenges
    • High treatment costs and stringent regulatory policy

Porter's Five Forces: A Strategic Tool for Navigating the Dermatology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dermatology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dermatology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dermatology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dermatology Drugs Market

A detailed market share analysis in the Dermatology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dermatology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dermatology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dermatology Drugs Market

A strategic analysis of the Dermatology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dermatology Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc by Abbvie Inc., Almirall S.A., Amgen Inc., Arcutis Biotherapeutics, Inc., Asterisk Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited, DermBiont, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., GlaxoSmithkline plc, Johnson & Johnson Services, Inc., Leo Pharma A/S, Lupin Ltd, Mayne Pharma Group Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc., Roivant Sciences Ltd., and Shinom Cosmeceuticals.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Antifungals, Corticosteroids, Immunosuppressants, and Retinoids.
  • Based on Route of Administration, market is studied across Oral, Parenteral Injection, and Topical.
  • Based on Indication Type, market is studied across Acne, Atopic dermatitis, Psoriasis, and Skin cancer.
  • Based on End-User, market is studied across Aesthetic & Dermatology Clinics, Diagnostic Centers & Laboratories, and Hospitals.
  • Based on Distribution Channel, market is studied across Hospital pharmacies and Retail pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
      • 5.1.1.2. Technological advancements in drug development, along with a strong pipeline of dermatological drugs
      • 5.1.1.3. Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent and time-consuming regulatory approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging investment in personalized medicine, and rising application in telemedicine
      • 5.1.3.2. Notable shift towards natural and organic ingredients in dermatological products
    • 5.1.4. Challenges
      • 5.1.4.1. High treatment costs and stringent regulatory policy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions
    • 5.2.2. End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dermatology Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Antifungals
  • 6.3. Corticosteroids
  • 6.4. Immunosuppressants
  • 6.5. Retinoids

7. Dermatology Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral Injection
  • 7.4. Topical

8. Dermatology Drugs Market, by Indication Type

  • 8.1. Introduction
  • 8.2. Acne
  • 8.3. Atopic dermatitis
  • 8.4. Psoriasis
  • 8.5. Skin cancer

9. Dermatology Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Aesthetic & Dermatology Clinics
  • 9.3. Diagnostic Centers & Laboratories
  • 9.4. Hospitals

10. Dermatology Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital pharmacies
  • 10.3. Retail pharmacies

11. Americas Dermatology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dermatology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dermatology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Almirall and Microsoft announce partnership for the development of novel treatments for skin diseases
    • 14.3.2. FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis
    • 14.3.3. Eli Lilly forays into dermatological space with launch of psoriasis drug
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan plc by Abbvie Inc.
  • 2. Almirall S.A.
  • 3. Amgen Inc.
  • 4. Arcutis Biotherapeutics, Inc.
  • 5. Asterisk Laboratories
  • 6. AstraZeneca plc
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • 11. DermBiont, Inc.
  • 12. Dr. Reddy's Laboratories
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche AG
  • 15. Galderma S.A.
  • 16. GlaxoSmithkline plc
  • 17. Johnson & Johnson Services, Inc.
  • 18. Leo Pharma A/S
  • 19. Lupin Ltd
  • 20. Mayne Pharma Group Ltd
  • 21. Merck & Co., Inc
  • 22. Novartis AG
  • 23. Pfizer Inc.
  • 24. Roivant Sciences Ltd.
  • 25. Shinom Cosmeceuticals

LIST OF FIGURES

  • FIGURE 1. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DERMATOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DERMATOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023